Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03400371

Biology of Juvenile Myoclonic Epilepsy

The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.

Recruiting

Interested in participating?

Request Info

Key information

Age range

10 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital for Sick Kids, Toronto, Ontario, Canada

Loading trial locations.

About this study

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 40% of patients have the common forms of Genetic Generalised Epilepsy (GGE), and the commonest GGE is "Juvenile Myoclonic Epilepsy" or JME.

The goal of this study is to find the genetic cause for JME. The investigators will do this by comparing the genetic code in JME patients with that in people who do not have epilepsy. This study will use clues from their electroencephalograph or brainwave test that is used to help diagnose epilepsy. Participants will provide a single blood sample, along with permission to collect clinical data about their diagnosis and a copy of their clinical EEG. There is no direct benefit or risk to the research participants but the results from this study may help other people with epilepsy or brain impairments in the future.

There is overwhelming evidence that JME is caused by changes in genetic code. These changes are likely to be found in more than just one gene and there may be more than one type of change. In order to find these changes, this study will look at a large number of people with JME and compare their genetic code with people who do not have epilepsy. Finding the causes of JME will lead to better understanding of its cause, new treatments, and tailoring of treatments according to a person's genetic make-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
  • Age of myoclonus onset 10-25 years
  • Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
  • EEG interictal generalized spikes and/or polyspike and waves with normal background
  • Current age 10-40 years

Exclusion criteria

  • Myoclonus only associated with carbamazepine or lamotrigine therapy
  • EEG showing predominant focal interictal epileptiform discharges or abnormal background
  • Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
  • Global learning disability
  • Dysmorphic syndrome
  • Unable to provide informed consent

Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.

Treatment and study plan

Blood Draw

Other

Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

Existing samples

Other

Control DNA samples will be used that have been previously acquired in other studies.

Primary outcomes

  1. Genomewide DNA association study

    Time frame: Day 1

    Association between SNP marker and phenotype is measured using genomewide DNA markers, which enables us to test support for molecular networks that act on seizure susceptibility

Secondary outcomes

  1. Quantitative EEG endophenotype

    Time frame: Day 1

    Brain network ictogenicity is measured using quantitative EEG data

Study contacts

Contact information is provided by the study sponsor or research team.

Deb K Pal, MD PhD

CONTACT

[email protected]

+442078480608

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Cardiff University
  • Charles University, Czech Republic
  • Hopital Universitaire Robert-Debre
  • King's College Hospital NHS Trust
  • Odense University Hospital
  • The Hospital for Sick Children
  • Vestre Viken Hospital Trust

Registry information

Acronym: BIOJUME

Important dates

Study start
2017
Primary completion
2026
Study completion
2026
First posted
Jan 17, 2018
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.